Udai S. Kammula

Best Publications

• Cancer regression in patients after transfer of genetically engineered lymphocytes

  Richard A. Morgan;Mark E. Dudley;John R. Wunderlich;Marybeth S. Hughes

  3824
  Citations

• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy

  Steven A. Rosenberg;James C. Yang;Richard M. Sherry;Udai S. Kammula

  2587
  Citations

• Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

  Mark E. Dudley;John R. Wunderlich;James C. Yang;Richard M. Sherry

  2110
  Citations

• Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

  Paul F. Robbins;Richard A. Morgan;Steven A. Feldman;James C. Yang

  1933
  Citations

• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

  James N. Kochenderfer;Mark E. Dudley;Steven A. Feldman;Wyndham H. Wilson

  1741
  Citations

• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

  Laura A. Johnson;Richard A. Morgan;Mark E. Dudley;Lydie Cassard

  1711
  Citations

• Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

  Mark E. Dudley;James C. Yang;Richard Sherry;Marybeth S. Hughes

  1663
  Citations

• Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

  Richard E. Royal;Catherine Levy;Keli Turner;Aarti Mathur

  1537
  Citations

• Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

  Richard A. Morgan;Nachimuthu Chinnasamy;Daniel Abate-Daga;Alena Gros

  1512
  Citations

• T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

  Maria R. Parkhurst;James C. Yang;Russell C. Langan;Mark E. Dudley

  1217
  Citations

• Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

  Peter Attia;Giao Q. Phan;Ajay V. Maker;Michael R. Robinson

  1146
  Citations

• Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis

  James C. Yang;Marybeth Hughes;Udai Kammula;Richard E Royal

  979
  Citations

• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

  Kimberly E. Beck;Joseph A. Blansfield;Khoi Q. Tran;Andrew L. Feldman

  939
  Citations

• A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

  Paul F. Robbins;Sadik H. Kassim;Thai Lan N. Tran;Jessica S. Crystal

  889
  Citations

• Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells

  Sanja Stevanović;Lindsey M. Draper;Michelle M. Langhan;Tracy E. Campbell

  816
  Citations

• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

  Stephanie G. Downey;Jacob A. Klapper;Franz O. Smith;James C. Yang

  735
  Citations

• CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

  Peter A. Prieto;James C. Yang;Richard M. Sherry;Marybeth S. Hughes

  659
  Citations

• Cancer therapy using a self-replicating RNA vaccine

  Han Ying;Tal Z. Zaks;Rong Fu Wang;Kari R. Irvine

  598
  Citations

• Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

  James N. Kochenderfer;Robert P.T. Somerville;Tangying Lu;Victoria Shi

  593
  Citations

• Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.

  Ajay V. Maker;Giao Q. Phan;Peter Attia;James C. Yang

  589
  Citations